Private clinical-stage psychedelics biotech Beckley Psytech announced it has successfully completed a Phase 1 clinical study on BPL-003, its patent-protected, synthetic intranasal formulation of 5-MeO-DMT under development for Treatment-Resistant Depression (TRD) and Alcohol Use Disorder (AUD.)

“We are pleased to report such positive initial findings from this Phase 1 study of BPL-003. The safety and tolerability profile, as well as the reliable induction of psychedelic experiences thus far, lay strong clinical foundations for BPL-003’s next stage of development and we are excited to move forward with our Phase 2 studies …

Full story available on Benzinga.com